Nasus Pharma (NSRX)
Develops powder-based nasal drugs for acute medical emergencies.
Something off on this page? Send us feedback.
Develops Nasax powder-based intranasal drug candidates for emergency conditions, led by NS002 epinephrine for severe allergic reactions. Its virtual model relies on external partners and has no approved products, sales organization or product revenue.
Develops powder-based intranasal drug candidates for acute medical emergencies through the proprietary Nasax platform. Its lead program, NS002, is a needle-free epinephrine candidate for severe allergic reactions and anaphylaxis; the portfolio also includes preclinical programs and a paused naloxone candidate available for partnering. None is FDA-approved, and NS002 remains in clinical development.
Operates as a virtual company from Israel, relying on external clinical, development, manufacturing and device partners rather than owned facilities, a sales force or a commercial product franchise. Technology is licensed from related-party Formulex, while Aptar is positioned to supply the unit-dose device for NS002 if approved. Most operational effort and financial resources are directed to NS002.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $11.8M · Total debt $103.0K · Total assets $12.4M · Shareholders' equity $11.0M
- Revenue
- $0
- Operating income
- −$6.0M
- Net income
- −$5.9M
No dividends on record.
| Insiders3 holders · as of Nov 13, 2025 | 60.07% | 5.17M shares | |
| Strategic holders1 holder · as of Aug 20, 2025 | 6.68% | 575.1K shares | |
| Otherremainder | 33.25% | 2.86M shares |
8.61M company shares as of Aug 22, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Udi GilboaInsider | 22.08% | 1.90M | 13Gfiled Nov 10, 2025 ↗ |
Dr. Dalia MegiddoInsider | 21.93% | 1.89M | 13Gfiled Nov 12, 2025 ↗ |
Dr. Ronnie HershmanInsider | 16.06% | 1.38M | 13Gfiled Nov 13, 2025 ↗ |
Capital Point Ltd.Strategic | 6.68% | 575,129 | 13Gfiled Aug 20, 2025 ↗ |
Balyasny Asset Management L.P.Institution | —9.99% of class, as filed | — | 13Gfiled May 15, 2026 ↗ |
| See all 6 → | |||
13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- ARS Pharmaceuticals
Approved neffy directly leads needle-free epinephrine rescue.
- Viatris
EpiPen is the entrenched injected epinephrine standard.
- Aquestive Therapeutics
Anaphylm targets needle-free epinephrine rescue by sublingual film.
- Emergent BioSolutions
NARCAN and KLOXXADO lead commercial nasal naloxone rescue.
- Teva (ADR)
Generic naloxone spray and epinephrine injection broaden rescue-market pressure.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nasus Pharma | $3.77 | −1.44% | $32.5M | — | — | — | — |
| ARS Pharmaceuticals | $5.82 | +0.87% | $577.9M | — | — | 4.9 | +114.2% |
| Viatris | $16.92 | −1.00% | $19.90B | — | 6.7 | 1.4 | +4.9% |
| Aquestive Therapeutics | $5.45 | +1.30% | $675.0M | — | — | 12.5 | +38.2% |
| Emergent BioSolutions | $6.42 | −0.70% | $333.3M | — | — | 0.4 | +66.3% |
| Teva (ADR) | $37.45 | −0.05% | $43.66B | 62.5 | 13.3 | 2.4 | −0.8% |
| Median | 62.5 | 10.0 | 2.4 | +38.2% |